MAYNE PHARMA ACQUIRES RIGHTS TO A PORTFOLIO OF GSK FOAM DERMATOLOGY PRODUCTS

18 August 2016, Adelaide, South Australia

- Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired a portfolio of dermatology foam products and related assets (“Foam Assets”) from GlaxoSmithKline (“GSK”) for US$50.1 million
- Fabior® and Sorilux® are complementary dermatology assets to Doryx® and will be marketed through Mayne Pharma’s established Specialty Brands Division
- Products expected to contribute modest incremental EBITDA in FY17 and have significant potential for growth in future years following re-launch

Mayne Pharma is pleased to announce it has acquired a portfolio of on-market dermatology Foam Assets from GSK for US$50.1 million. The Foam Assets include US rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® and Mexican rights to betamethasone foam. Under the terms of the agreement Mayne Pharma will acquire the approved regulatory filings, trademarks, marketing materials, select product inventory, related medical and technical data and will acquire or obtain licenses for related patents.

Fabior (tazarotene) Foam, 0.1% is a patent-protected topical product indicated for the treatment of acne, the largest dermatology indication in the US affecting up to 50 million Americans every year1. Sorilux (calcipotriene) Foam, 0.005% is a patent-protected topical product indicated for mild to moderate plaque psoriasis affecting up to 6 million Americans each year1.

Both Fabior and Sorilux will be marketed through Mayne Pharma’s Specialty Brands Division and existing sales team. Re-launch for both products is expected in FY17. During the intervening period GSK will continue to distribute Fabior and Sorilux under a transition services arrangement.

The non-US dermatology assets will continue to be distributed by GSK in the short term and Mayne Pharma will seek to out-license these products to new partners.

Rationale for the acquisition

Mayne Pharma’s CEO, Mr Scott Richards said “This acquisition will strengthen Mayne Pharma’s position in the US dermatology market, diversify future branded earnings and create new opportunities for growth. Both Fabior and Sorilux are a strategic fit with the existing Doryx franchise and participate in attractive and growing markets. We believe both products are differentiated assets with compelling clinical data that physicians and patients will appreciate.”

1 American Academy of Dermatology
“Mayne Pharma is very attracted to the underlying fundamentals of the US dermatology market. The acquisition will leverage existing commercial infrastructure across functions including sales and marketing, customer service, compliance, medical affairs and contracts administration. We also expect to leverage the new foam capability in future branded and generic product development programs.”

Mayne Pharma expects the products to contribute modest incremental EBITDA in FY17 and have significant potential for growth in future years.

Further information

Shareholders are advised to refer to the “Acquisition of GSK Foam Assets” presentation released to the ASX on 18 August 2016 for further detail of the acquisition.

For further information contact:
Scott Richards  +61 3 8614 7777
Lisa Pendlebury  +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products globally - either directly or through distribution partners, while applying its drug delivery expertise for contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, NC, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

About Sorilux
Sorilux Foam contains calcipotriene, a synthetic vitamin D3 analogue. It is indicated for the topical treatment of plaque psoriasis in patients aged 18 years and older. Plaque psoriasis is a chronic, non-contagious, inflammatory skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp and knees but can also affect other parts of the body. Full prescribing information for Sorilux is available here.

About Fabior
Fabior is a retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older. Fabior Foam is not for oral, ophthalmic, or intravaginal use. Full prescribing information for Fabior is available here.